Skip to main content
. Author manuscript; available in PMC: 2017 Dec 14.
Published in final edited form as: Leuk Res. 2016 Sep 26;50:85–94. doi: 10.1016/j.leukres.2016.09.018

Fig. 3.

Fig. 3

Decitabine restored the silenced expression of NR4A3 accompanied by demethylation at the region encompassing exon 3 of NR4A3.

(A–B) AML cell lines, in which the region encompassing exon 3 is heavily methylated, were treated with different doses of decitabine (DAC) for 48 and 72 h. (A) mRNA levels of NR4A3 in the cells were evaluated by quantitative real-time PCR and normalized to GAPDH expression. Data are shown as the mean ± S.D. for triplicate analyses. (B) The methylation status of CpG sites at the region encompassing exon 3 of NR4A3 in AML cell lines was analyzed before and after DAC exposure using bisulfite sequencing. The percentages of methylation at each CpG site are indicated by black coloring in pie charts. The percentages of methylation of the total CpG sites in the region of PCR products are also indicated with an average. **, P < 0.01; ***, P < 0.001